The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2017 | Pembrolizumab: a promising agent for the treatment of MM
Nikhil Munshi, MD, PhD, from the Dana-Farber Cancer Institute, Boston, MA, USA, discusses the use of pembrolizumab in treating multiple myeloma (MM), presented at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain. As it has been observed that pembrolizumab may exert a synergistic therapeutic effect, studies involving the combination of pembrolizumab with other agents such as lenalidomide and pomalidomide have been evaluated and found to significantly improve response rates in MM patients, as explained by Dr. Munshi. From this, it appears that the future for pembrolizumab in the treatment of MM is promising.
